Prognostic and clinicopathological role of pretreatment fibrinogen-to-albumin ratio (FAR) in patients with gastric cancer: a meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
5665 cases in the present work.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] In the present study, increased FAR dramatically predicted the dismal OS of GC. Moreover, high FAR showed obvious relation to older age, larger tumor size, and advanced stage of GC cases.
[BACKGROUND] Fibrinogen-to-albumin ratio (FAR) has been previously suggested for its significance in forecasting gastric cancer (GC) prognosis, however, the results remained conflicting.
- p-value p < 0.001
- OR 2.13
- HR 1.68
- 연구 설계 meta-analysis
APA
Wang J, Zhang Z, Fei P (2025). Prognostic and clinicopathological role of pretreatment fibrinogen-to-albumin ratio (FAR) in patients with gastric cancer: a meta-analysis.. World journal of surgical oncology, 23(1), 227. https://doi.org/10.1186/s12957-025-03885-0
MLA
Wang J, et al.. "Prognostic and clinicopathological role of pretreatment fibrinogen-to-albumin ratio (FAR) in patients with gastric cancer: a meta-analysis.." World journal of surgical oncology, vol. 23, no. 1, 2025, pp. 227.
PMID
40495195 ↗
Abstract 한글 요약
[BACKGROUND] Fibrinogen-to-albumin ratio (FAR) has been previously suggested for its significance in forecasting gastric cancer (GC) prognosis, however, the results remained conflicting. The present work focused on clarifying FAR's accurate effect on forecasting GC prognosis via meta-analysis.
[METHODS] This study thoroughly retrieved PubMed, Web of Science, Embase, Cochrane Library, and CNKI until January 4, 2025, and determined pooled hazard ratios (HRs) and 95% confidence intervals (CIs) to forecast FAR's role in forecasting GC overall survival (OS) and disease-free survival (DFS).
[RESULTS] We retrieved 12 studies recruiting 5665 cases in the present work. From the pooled findings, high FAR exhibited significant relation to unfavorable OS (HR = 1.68, 95%CI = 1.38-2.04, p < 0.001) of patients with GC. But FAR was not apparently linked with DFS of GC (HR = 1.24, 95%CI = 0.69-2.22, p = 0.468). According to our combined findings, elevated FAR exhibited significant connection to age ≥ 60 years (OR = 2.13, 95%CI = 1.72-2.65, p < 0.001), tumor size ≥ 5 cm (OR = 1.91, 95%CI = 1.13-3.24, p = 0.016), and TNM stage of III-IV (OR = 2.5, 95%CI = 2.08-3.23, p < 0.001). Nonetheless, FAR remained insignificantly linked with gender (OR = 1.16, 95%CI = 0.94-1.43, p = 0.162), invasion depth (OR = 2.01, 95%CI = 1.00-4.04, p = 0.050), N stage (OR = 1.30, 95%CI = 0.63-2.67, p = 0.482), tumor differentiation (OR = 1.22, 95%CI = 0.93-1.62, p = 0.153), and vascular invasion (OR = 1.11, 95%CI = 0.68-1.81, p = 0.687) of GC patients.
[CONCLUSION] In the present study, increased FAR dramatically predicted the dismal OS of GC. Moreover, high FAR showed obvious relation to older age, larger tumor size, and advanced stage of GC cases.
[METHODS] This study thoroughly retrieved PubMed, Web of Science, Embase, Cochrane Library, and CNKI until January 4, 2025, and determined pooled hazard ratios (HRs) and 95% confidence intervals (CIs) to forecast FAR's role in forecasting GC overall survival (OS) and disease-free survival (DFS).
[RESULTS] We retrieved 12 studies recruiting 5665 cases in the present work. From the pooled findings, high FAR exhibited significant relation to unfavorable OS (HR = 1.68, 95%CI = 1.38-2.04, p < 0.001) of patients with GC. But FAR was not apparently linked with DFS of GC (HR = 1.24, 95%CI = 0.69-2.22, p = 0.468). According to our combined findings, elevated FAR exhibited significant connection to age ≥ 60 years (OR = 2.13, 95%CI = 1.72-2.65, p < 0.001), tumor size ≥ 5 cm (OR = 1.91, 95%CI = 1.13-3.24, p = 0.016), and TNM stage of III-IV (OR = 2.5, 95%CI = 2.08-3.23, p < 0.001). Nonetheless, FAR remained insignificantly linked with gender (OR = 1.16, 95%CI = 0.94-1.43, p = 0.162), invasion depth (OR = 2.01, 95%CI = 1.00-4.04, p = 0.050), N stage (OR = 1.30, 95%CI = 0.63-2.67, p = 0.482), tumor differentiation (OR = 1.22, 95%CI = 0.93-1.62, p = 0.153), and vascular invasion (OR = 1.11, 95%CI = 0.68-1.81, p = 0.687) of GC patients.
[CONCLUSION] In the present study, increased FAR dramatically predicted the dismal OS of GC. Moreover, high FAR showed obvious relation to older age, larger tumor size, and advanced stage of GC cases.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- "A diamond-shaped" penoplasty technique with or without concurrent suprapubic liposuction for adult-acquired buried penis: clinical outcomes and patient satisfaction rates.
- A Systematic Review of Patient-Reported Outcomes for Cosmetic Indications of Botulinum Toxin Treatment.
- Impact of diagnosis-related group systems on inpatient expenditures and medical quality for children with leukemia: evidence from real-world data.
- A preliminary study to evaluate efficacy and safety of Lugol's solution following radioiodine for remnant ablation in differentiated thyroid cancer.
- Lentinan inhibits breast cancer cell growth through the dual downregulation of tumor-promoting effectors CD133 and SCGB2A2.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.